NotesFAQContact Us
Collection
Advanced
Search Tips
Peer reviewed Peer reviewed
Direct linkDirect link
ERIC Number: EJ821873
Record Type: Journal
Publication Date: 2009
Pages: 11
Abstractor: As Provided
Reference Count: N/A
ISBN: N/A
ISSN: ISSN-0891-4222
Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children
Aman, Michael G.; Hollway, Jill A.; Leone, Sarah; Masty, Jessica; Lindsay, Ronald; Nash, Patricia; Arnold, L. Eugene
Research in Developmental Disabilities: A Multidisciplinary Journal, v30 n2 p386-396 Mar-Apr 2009
This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2 weeks each. Dependent measures included tests of sustained attention, memory, visual matching, tremor, seat activity, abnormal movements, and parent behavior ratings. Results were compared by repeated measures ANOVA. Fourteen boys and 2 girls with disruptive behavior and IQ [less than or equal to] 84 all completed the protocol. Risperidone was superior to placebo on response time (p = 0.01, [eta][subscript P][superscript 2] = 0.43) and seat movement (p less than 0.05, [eta][subscript P][superscript 2] = 0.29) on a short-term memory task, and on a measure of static tremor (p = 0.05, [eta][subscript P][superscript 2] = 0.28). There was not a significant difference between treatment conditions on the Abnormal Involuntary Movement scale. Risperidone was superior to placebo on three subscales of the Nisonger Child Behavior Rating Form [Overly Sensitive (p less than 0.01, [eta][subscript P][superscript 2] = 0.44), Conduct Problem (p = 0.02, [eta][subscript P][superscript 2] = 0.36), Hyperactivity (p = 0.03, [eta][subscript P][superscript 2] = 0.32)] and on the Hyperactivity/Noncompliance subscale of the Aberrant Behavior Checklist (p = 0.01, [eta][subscript P][superscript 2] = 0.41). Significant increases in heart rate (p = 0.05, [eta][subscript P][superscript 2] = 0.27) and weight (p = 0.02, [eta][subscript P][superscript 2] = 0.36) occurred in the risperidone condition. The findings suggest a beneficial effect of risperidone after several months of treatment on efficiency of responding, activity level, static tremor, and aspects of behavior. (Contains 3 tables.)
Elsevier. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Tel: 877-839-7126; Tel: 407-345-4020; Fax: 407-363-1354; e-mail: usjcs@elsevier.com; Web site: http://www.elsevier.com
Publication Type: Journal Articles; Reports - Research
Education Level: N/A
Audience: N/A
Language: English
Sponsor: N/A
Authoring Institution: N/A
Identifiers - Assessments and Surveys: Aberrant Behavior Checklist